Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D2.151 - HZ-Y030, an Oral STAT6 Degrader, Attenuates Type 2 Inflammation in Preclinical Asthma Models
D2.152 - Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma
D2.155 - Mapping the Architecture and Spectrum of the Cough Hypersensitivity Questionnaire Across Respiratory Diseases
D2.158 - Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma
D2.157 - Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study
D2.159 - Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
D2.160 - Household Overcrowding and Number of Siblings as Risk Factors for Uncontrolled Asthma in Inner-City Children
D2.161 - Exploring the Early-Life Interplay Between Respiratory Health and Neurodevelopmental disorders
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study
D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis
D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to
D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study
D3.288 - Evaluating the role of dust mite sensitization in the development of edible insect allergies
D3.289 - Tolerance Assessment in Children with IgE-Mediated Cow's Milk Allergy Using Different Cutoff Values of Cow’s Milk Specific IgE
D3.284 - Milk Aversion After Successful Desensitization in a Milk-Allergic Child
D3.283 - Oat-Induced Anaphylaxis: Allergenic Characterization in a Clinical Case
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download